{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,3]],"date-time":"2022-04-03T23:46:38Z","timestamp":1649029598322},"reference-count":10,"publisher":"Japanese Urological Association","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Jpn. j. urol"],"published-print":{"date-parts":[[2011]]},"DOI":"10.5980\/jpnjurol.102.701","type":"journal-article","created":{"date-parts":[[2012,10,9]],"date-time":"2012-10-09T23:03:27Z","timestamp":1349823807000},"page":"701-704","source":"Crossref","is-referenced-by-count":0,"title":["EXPERIENCE WITH GEMCITABINE MONOTHERAPY IN THREE PATIENTS WITH METASTATIC UROTHELIAL CARCINOMA"],"prefix":"10.5980","volume":"102","author":[{"given":"Yuuki","family":"Kyoda","sequence":"first","affiliation":[{"name":"Department of Urology, Hokkaido Social Work Association Obihiro Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuharu","family":"Kunishima","sequence":"additional","affiliation":[{"name":"Department of Urology, Hokkaido Social Work Association Obihiro Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumimasa","family":"Fukuta","sequence":"additional","affiliation":[{"name":"Department of Urology, Hokkaido Social Work Association Obihiro Hospital"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4001","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Saxman SB, Propert KJ, Einhorn LH, Crawford ED, Tannock I, Raghavan D, Loehrer PJ Sr and Trump D: Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol, 15, 2564-2569, 1997.","DOI":"10.1200\/JCO.1997.15.7.2564"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) von der Maase H: Gemcitabine in transitional cell carcinoma of the urothelium. Expert Rev Anticancer Ther, 3, 11-19, 2003.","DOI":"10.1586\/14737140.3.1.11"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, Bodrogi I, Albers P, Knuth A, Lippert CM, Kerbrat P, Sanchez Rovira P, Wersall P, Cleall SP, Roychowdhury DF, Tomlin I, Visseren-Grul CM and Conte PF: Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol, 18, 3068-3077, 2000.","DOI":"10.1200\/JCO.2000.18.17.3068"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Robinson P, Maase H, Bhalla S, Kielhorn A, Aristides M, Brown A and Tilden D: Cost-utility analysis of the GC versus MVAC regimens for the treatment of locally advanced or metastatic bladder cancer. Expert Rev Pharmacoecon Outcomes Res, 4, 27-38, 2004.","DOI":"10.1586\/14737167.4.1.27"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Dash A, Galsky MD, Vickers AJ, Serio AM, Koppie TM, Dalbagni G and Bochner BH: Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder. Cancer, 107, 506-513, 2006.","DOI":"10.1002\/cncr.22031"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Cho KS, Joung JY, Seo HK, Cho IC, Chung HS, Chung J and Lee KH: Renal safety and efficacy of cisplatin-based chemotherapy in patients with a solitary kidney after nephroureterectomy for urothelial carcinoma of the upper urinary tract. Cancer Chemother Pharmacol, 2010 (in press).","DOI":"10.1007\/s00280-010-1349-2"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Akaza H, Naito S, Usami M, Miki T, Miyanaga N and Taniai H: Efficacy and safety of gemcitabine monotherapy in patients with transitional cell carcinoma after Cisplatin-containing therapy: a Japanese experience. Jpn J Clin Oncol, 37, 201-206, 2007.","DOI":"10.1093\/jjco\/hym011"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Lorusso V, Pollera CF, Antimi M, Luporini G, Gridelli C, Frassineti GL, Oliva C, Pacini M and De Lena M: A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer. Eur J Cancer, 34, 1208-1212, 1998.","DOI":"10.1016\/S0959-8049(98)00030-6"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Soga N, Kise H, Arima K and Sugimura Y: Third-line gemcitabine monotherapy for platinum-resistant advanced urothelial cancer. Int J Clin Oncol, 15, 376-381, 2010.","DOI":"10.1007\/s10147-010-0071-8"},{"key":"10","unstructured":"10) Ecke TH, Gerullis H, Bartel P, Koch S and Ruttloff J: Palliative chemotherapy with gemcitabine, paclitaxel, and cisplatin as first-line treatment following gemcitabine monotherapy for patients with transitional cell carcinoma of the urothelium. Minerva Urol Nefrol, 61, 1-8, 2009."}],"container-title":["The Japanese Journal of Urology"],"original-title":["Gemcitabine\u5358\u72ec\u7642\u6cd5\u3092\u65bd\u884c\u3057\u305f\u8ee2\u79fb\u6027\u5c3f\u8def\u4e0a\u76ae\u764c\u306e3\u4f8b"],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jpnjurol\/102\/5\/102_701\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,7,4]],"date-time":"2019-07-04T14:57:18Z","timestamp":1562252238000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jpnjurol\/102\/5\/102_701\/_article\/-char\/ja\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011]]},"references-count":10,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.5980\/jpnjurol.102.701","relation":{},"ISSN":["0021-5287","1884-7110"],"issn-type":[{"value":"0021-5287","type":"print"},{"value":"1884-7110","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011]]}}}